Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Subcision With CO₂ Laser or PRP vs Subcision Alone in Atrophic Acne Scars

NCT07199608 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-11
Last updated
2025-10-03

Condition(s) studied

Atrophic Acne Scar

Investigational drug(s) / intervention(s)

subcisionsubcision+fractional co2 lasersubcision+PRP

subcision: patients will undergo subcision procedure alone using 18 gauge blunt cannula to release fibrous bands under atrophic acne scars.this group will serve as control comparator

subcision+fractional co2 laser: patients will undergo subcision procedure followed by fractional co2 laser applied to right side of face, the left side will receive subcision alone

subcision+PRP: patients will undergo subcision procedure followed by intradermal injection of autologous PRP prepared from patients blood on right side.left side will receive subcision alone

Study summary

Acne vulgaris is an inflammatory disease of pilosebaceous unit ,leading to different types of scars including atrophic, hypertrophic and keloidal. Atrophic scars are the most common type ,affecting about 75-90% of acne scar cases and can be ice pick, rolling or boxcar in morphology . Theses scars may cause significant impact such as depression, anxiety , and reduced quality of life. multiple treatment modalities exist, including lasers ,chemical peels, dermabrasion, microneedling, subcision and platelet rich plasma. Subcision is a well established technique that improves rolling and boxcar scars by releasing fibrotic strands. Fractional co2 laser induces dermal remodeling and collagen neogenesis, while PRP enhances wound healing and collagen induction through growth factors. Combinig subcision with either co2 laser or PRP may enhance treatment efficacy compared to subcision alone.

rational : Subcision alone may provide limited improvement in some patients. Fractional CO₂ laser and PRP are promising adjunctive modalities that could enhance collagen remodeling and improve cosmetic outcomes. Evaluating their combined effect versus subcision alone will help determine the most effective and safe approach for managing atrophic post-acne scars.

aim of work:To compare the efficacy and safety of combined subcision with either fractional CO₂ laser or platelet-rich plasma versus subcision alone in the treatment of facial atrophic post-acne scars.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * \- Adult patients of both sexes with mild to severe atrophic post-acne scars. Exclusion Criteria: * \- Age \< 18 years * Pregnant or lactating women * Active inflammatory acne or infection in treatment area * Premalignant or malignant lesions * Photosensitive dermatoses * Coagulation defects or blood disease * History of keloid scars * Systemic retinoid use in previous 6 months

Primary outcome measure(s)

  • Change in Goodman and Baron quantitative acne scar score (Baseline vs 1 month post last session). — 3 sessions per patient at 1-month intervals Follow-up: 1 month after last session
    If the scale was lowered by: (Quantitative) 0-5 points, the reduction will be considered minimal 5-10 points, it will be considered moderate reduction 10-15 points, it will be considered good reduction \>15 points, it will be considered very good reduction

Trial sites (1)

FacilityCityRegionStatus
Assiut University Hospitals, Dermatology Department Asyut Asyut Governorate
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07199608 on ClinicalTrials.gov ↗ ← All trials in Egypt